Clinically accurate diagnosis of Alzheimer’s disease via multiplexed sensing of core biomarkers in human plasma

Kim, Kayoung; Kim, Minji; Kim, Da Won; Kim, Su Yeong; Park, Steve; Park, Chan Beum

doi:10.1038/s41467-019-13901-z

Cited by 173 publications

(122 citation statements)

References 41 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…The black bars indicate minor transcripts that encode proteins in a different reading frame from the overlapping major mRNA. Reproduced with permission from ( Kim et al, 2020c ). (E) Phylogenetic tree of SARS-CoV-2 and other pathogenic human CoVs, including HCoV-229E, HCoV-HKU1, HCoV-NL63 HCoV-OC43, and MERS-CoV.…”

Section: Overview Of Sars-cov-2mentioning

confidence: 99%

“…The high-sensitivity of G-FET was also recently used to detect SARS-CoV-2 virus particles in human NS specimens ( Seo et al, 2020 ). Moreover, carbon nanotube-based FET sensors have shown great promise for the highly sensitive detection of virus antigens, antibodies, nucleic acids, and virus particles in clinical samples ( Choi et al, 2017 ; Kim et al, 2020b ; Mandal et al, 2012 ; Oh et al, 2013 ; Ramnani et al, 2013 ; Son et al, 2016 ).…”

Section: Potential Biosensors For Point-of-care Sars-cov-2 Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of COVID-19: A review of the current literature and future perspectives

Liu

Wang

et al. 2020

Biosensors and Bioelectronics

350

309

View full text Add to dashboard Cite

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the coronavirus disease 2019 (COVID-19) worldwide pandemic. This unprecedented situation has garnered worldwide attention. An effective strategy for controlling the COVID-19 pandemic is to develop highly accurate methods for the rapid identification and isolation of SARS-CoV-2 infected patients. Many companies and institutes are therefore striving to develop effective methods for the rapid detection of SARS-CoV-2 ribonucleic acid (RNA), antibodies, antigens, and the virus. In this review, we summarize the structure of the SARS-CoV-2 virus, its genome and gene expression characteristics, and the current progression of SARS-CoV-2 RNA, antibodies, antigens, and virus detection. Further, we discuss the reasons for the observed false-negative and false-positive RNA and antibody detection results in practical clinical applications. Finally, we provide a review of the biosensors which hold promising potential for point-of-care detection of COVID-19 patients. This review thereby provides general guidelines for both scientists in the biosensing research community and for those in the biosensor industry to develop a highly sensitive and accurate point-of-care COVID-19 detection system, which would be of enormous benefit for controlling the current COVID-19 pandemic.

show abstract

Section: Overview Of Sars-cov-2mentioning

confidence: 99%

Section: Potential Biosensors For Point-of-care Sars-cov-2 Detectionmentioning

confidence: 99%

Detection of COVID-19: A review of the current literature and future perspectives

Liu

Wang

et al. 2020

Biosensors and Bioelectronics

350

309

View full text Add to dashboard Cite

show abstract

“…Perez-Grijalba et al showed that a decreased plasma Aβ42/Aβ40 ratio alone can accurately predict positivity and detect early stages of AD [76,77]. Using a multiplex sensor array, Kim et al showed that a lower Aβ42/Aβ40 ratio and a higher plasma t-tau/Aβ42 and p-tau 181/Aβ42 ratios successfully discriminated AD patients from healthy controls [78]. In addition to plasma Aβ levels, Nabers et al showed that a change in the secondary structure of Aβ in human blood plasma can be used as a blood amyloid indicator for prodromal AD.…”

Section: Blood Aβ Markersmentioning

confidence: 99%

“…Consistently decreased in CSF, also decreased in blood [20][21][22][23][24][25][26][27][28][29][74][75][76][77][78]…”

Section: Aβ42mentioning

confidence: 99%

Current Biomarkers for Alzheimer’s Disease: From CSF to Blood

Zou

Abdullah

Michikawa

2020

JPM

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common cause of dementia and affects a large portion of the elderly population worldwide. Currently, a diagnosis of AD depends on the clinical symptoms of dementia, magnetic resonance imaging to determine brain volume, and positron emission tomography imaging to detect brain amyloid or tau deposition. The best characterized biological fluid markers for AD are decreased levels of amyloid β-protein (Aβ) 42 and increased levels of phosphorylated tau and total tau in cerebrospinal fluid (CSF). However, less invasive and easily detectable biomarkers for the diagnosis of AD, especially at the early stage, are still under development. Here, we provide an overview of various biomarkers identified in CSF and blood for the diagnostics of AD over the last 25 years. CSF biomarkers that reflect the three hallmarks of AD, amyloid deposition, neurofibrillary tangles, and neurodegeneration, are well established. Based on the need to start treatment in asymptomatic people with AD and to screen for AD risk in large numbers of young, healthy individuals, the development of biomarkers for AD is shifting from CSF to blood. Elements of the core pathogenesis of AD in blood, including Aβ42, tau proteins, plasma proteins, or lipids have shown their usefulness and capabilities in AD diagnosis. We also highlight some novel identified blood biomarkers (including Aβ42/Aβ43, p-tau 181, Aβ42/APP669-711, structure of Aβ in blood, and flotillin) for AD.

show abstract

“…5 . This was used to measure levels of AD biomarkers using fluorescence and resistance measurement techniques, showing LOD values of 2.45, 2.72, 2.20, and 2.13 fM/mL for t-tau, p-tau181, Aβ42, and Aβ40, respectively [ 146 ]. An electrochemical immunoassay has been developed by Diba et al from sandwich immunoassay fabricated with an antibody coated on a monolayer obtained by mixing 3-mercaptopropionic acid (MPA) and thiol modified polyethylene glycol (PEG-SH) localized on AuNPs over the screen printed carbon electrode (SPCE).…”

Section: Introductionmentioning

confidence: 99%

Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease

et al. 2021

View full text Add to dashboard Cite

This review highlights current developments, challenges, and future directions for the use of invasive and noninvasive biosample-based small biosensors for early diagnosis of Alzheimer’s disease (AD) with biomarkers to incite a conceptual idea from a broad number of readers in this field. We provide the most promising concept about biosensors on the basis of detection scale (from femto to micro) using invasive and noninvasive biosamples such as cerebrospinal fluid (CSF), blood, urine, sweat, and tear. It also summarizes sensor types and detailed analyzing techniques for ultrasensitive detection of multiple target biomarkers (i.e., amyloid beta (Aβ) peptide, tau protein, Acetylcholine (Ach), microRNA137, etc.) of AD in terms of detection ranges and limit of detections (LODs). As the most significant disadvantage of CSF and blood-based detection of AD is associated with the invasiveness of sample collection which limits future strategy with home-based early screening of AD, we extensively reviewed the future trend of new noninvasive detection techniques (such as optical screening and bio-imaging process). To overcome the limitation of non-invasive biosamples with low concentrations of AD biomarkers, current efforts to enhance the sensitivity of biosensors and discover new types of biomarkers using non-invasive body fluids are presented. We also introduced future trends facing an infection point in early diagnosis of AD with simultaneous emergence of addressable innovative technologies.

show abstract

Clinically accurate diagnosis of Alzheimer’s disease via multiplexed sensing of core biomarkers in human plasma

Cited by 173 publications

References 41 publications

Detection of COVID-19: A review of the current literature and future perspectives

Detection of COVID-19: A review of the current literature and future perspectives

Current Biomarkers for Alzheimer’s Disease: From CSF to Blood

Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease

Contact Info

Product

Resources

About